Recombinant assay for serodiagnosis of Lyme disease regardless of OspA vaccination status

被引:17
作者
Gomes-Solecki, MJC
Wormser, GP
Schriefer, M
Neuman, G
Hannafey, L
Glass, JD
Dattwyler, RJ [2 ]
机构
[1] Brook Biotechnol Inc, Stony Brook, NY 11790 USA
[2] SUNY Stony Brook, Dept Med, Div Clin Immunol, Stony Brook, NY 11794 USA
[3] New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA
[4] Wampole Labs, Cranbury, NJ 08512 USA
[5] Ctr Dis Control & Prevent, Ft Collins, CO 80522 USA
关键词
D O I
10.1128/JCM.40.1.193-197.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
All current seroassays using cultured Borrelia burgdorferi as their antigen source have been rendered obsolete by the recombinant OspA Lyme disease vaccine. OspA is the major outer surface protein expressed in cultured A burgdorferi, and any seroassay that uses whole organisms as its antigen source cannot differentiate between subjects who received the vaccine and those who were naturally infected. We developed a new sensitive and specific enzyme-linked immunosorbent assay (ELISA) utilizing recombinant chimeric borrelia proteins devoid of OspA (rNon-OspA) that can be used to detect antibodies to diagnostically important B. burgdorferi antigens in both OspA-vaccinated and nonvaccinated individuals. We tested sera from patients with Lyme disease and with conditions associated with false-positive serologies, OspA-vaccinated individuals, and healthy high-risk workers from an area of endemicity and normal sera from individuals from areas of nonendemicity. The rNon-OspA test was compared with two commercially available whole-cell immunoassays. The rNon-OspA assay is as sensitive and specific as the whole-cell assay (P > 0.05) for detection of anti-B. burgdorferi antibodies. However, the rNon-OspA assay can differentiate between populations comprised of naturally infected and OspA-vaccinated individuals (P < 0.05). Our data demonstrate that this new sensitive rNon-OspA ELISA can be used for the laboratory detection of B. burgdorferi antibodies regardless of vaccination status and could replace existing serologic assays for Lyme disease.
引用
收藏
页码:193 / 197
页数:5
相关论文
共 25 条
[1]   Effects of OspA vaccination on Lyme disease serologic testing [J].
Aguero-Rosenfeld, ME ;
Roberge, J ;
Carbonaro, CA ;
Nowakowski, J ;
Nadelman, RB ;
Wormser, GP .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (11) :3718-3721
[2]  
*CDCP, 2001, MMWR-MORBID MORTAL W, V50, P181
[3]  
Centers for Disease Control and Prevention, 1995, MORB MORTAL WKLY RE, V44, P590
[4]   Effect of immunization with recombinant OspA on serologic tests for lyme borreliosis [J].
Fawcett, PT ;
Rose, CD ;
Budd, SM ;
Gibney, KM .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2001, 8 (01) :79-84
[5]  
GOLESSOLECKI M, 2001, ARCH INTERN MED, V161, P2015
[6]  
Gomes-Solecki MJC, 2000, J CLIN MICROBIOL, V38, P2530
[7]   LABORATORY DIAGNOSTIC METHODS IN LYME BORRELIOSIS [J].
HANSEN, K .
CLINICS IN DERMATOLOGY, 1993, 11 (03) :407-414
[8]  
JIANG W, 1990, J IMMUNOL, V144, P284
[9]   Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi [J].
Lawrenz, MB ;
Hardham, JM ;
Owens, RT ;
Nowakowski, J ;
Steere, AC ;
Wormser, GP ;
Norris, SJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3997-4004
[10]   Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE [J].
Liang, FT ;
Steere, AC ;
Marques, AR ;
Johnson, BJB ;
Miller, JN ;
Philipp, MT .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) :3990-3996